M. Tonda

发表

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

K. Bridges, K. Dufu, J. Howard, 2016 .

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

V. Gordeuk, Winfred C. Wang, Y. Yaron, 2017 .

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.

F. Khuri, W. Hong, R. Herbst, 2001, Lung cancer.

Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.

Michelle L. Green, R. Savic, C. Washington, 2022, CPT: pharmacometrics & systems pharmacology.

Voxelotor for the treatment of sickle cell disease in pediatric patients

M. Abboud, Clark Brown, M. Tonda, 2022, Expert review of hematology.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

K. Dufu, J. Howard, P. Telfer, 2019, Blood.

A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.

D. Henry, T. Cooley, Steven Sun, 2007, The oncologist.

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy

W. Meyer, W. Furman, C. Pratt, 1997, Cancer Chemotherapy and Pharmacology.

Formation of Platinum‐DNA Adducts in Pediatric Patients Receiving Carboplatin

D. Murry, J. Rodman, M. Tonda, 1996, Pharmacotherapy.

Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts

S. Strychor, W. Zamboni, J. Eiseman, 2007, Clinical Cancer Research.

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

K. Ataga, E. Vichinsky, R. Ware, 2019, The New England journal of medicine.

Treatment of Acute Neuroleptic‐Induced Movement Disorders

Sally K. Guthrie, M. Tonda, S. K. Guthrie, 1994, Pharmacotherapy.

Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.

S. Ramalingam, S. Strychor, W. Zamboni, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allometric scaling of STEALTH® liposomal anticancer agents

S. Strychor, W. Zamboni, R. Dedrick, 2005 .

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

K. Ataga, E. Vichinsky, I. Agodoa, 2020 .

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease

B. Biemond, J. Knight-Madden, C. Minniti, 2021, American journal of hematology.

Plasma , Tumor , andTissue Disposition of STEALTHLiposomal CKD-602 ( S-CKD 602 ) and Nonliposomal CKD-602 in Mice Bearing A 375 HumanMelanoma Xenografts

S. Strychor, W. Zamboni, J. Eiseman, 2007 .

Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years

A. Inati, R. Kalpatthi, N. Griffin, 2022, Pediatric blood & cancer.

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

L. Burke, K. Fox, I. Agodoa, 2018, Hematology reports.

Carboplatin pharmacokinetics in young children with brain tumors

H. Friedman, W. Petros, D. Murry, 1996, Cancer Chemotherapy and Pharmacology.

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.

K. Ataga, E. Vichinsky, I. Agodoa, 2021, The Lancet. Haematology.

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

Steven Sun, M. Tonda, A. Gordon, 2004, Gynecologic oncology.

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models

S. Strychor, W. Zamboni, P. Basse, 2011, Journal of liposome research.

A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer

G. Weinstein, R. Weber, A. Chalian, 2002, Investigational New Drugs.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, T. Lynch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Allometric scaling of pegylated liposomal anticancer drugs

J. Schellens, J. Beijnen, H. Clewell, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

J. Schellens, M. Egorin, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015 .

Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors

S. Strychor, S. Ramalingam, W. Zamboni, 2005 .

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Clark Brown, D. Archer, J. Lehrer-Graiwer, 2019, Blood.

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

K. Ataga, E. Vichinsky, V. Gordeuk, 2020 .